MA-IBASIS
14.5.2024 14:01:39 CEST | Business Wire | Press release
iBASIS, the leading provider of communications solutions for operators and digital players worldwide, and Altice Dominicana, one of the leading mobile networks in the Dominican Republic, announced today that they have renewed their successful outsourcing agreement for voice services.
Since its sale by Altice in 2018, iBASIS and its global team have been dedicated to bringing Altice Dominicana best-in-class services, leveraging the group consolidation and economy of scale strategy of its owner, Tofane Global. iBASIS has helped to drive the Dominican operator’s performance, monetization, and profitability through its differentiated model, international expertise, and exclusive Inbound Gateway. Key focus areas, including cost improvement and fraud prevention, have also played a pivotal role in supporting Altice Dominicana’s sustained traffic growth.
“iBASIS demonstrated their commitment to deliver value across many facets of our international business. Their offerings and expertise, specifically in addressing international requirements, enable us to make significant service quality enhancements and cost improvements,” said Jennifer Espinal, International Business Manager at Altice Dominicana. “The strategic relationship, including the exclusive Inbound Gateway, is essential for maintaining our growth trajectory and securing our leading position in the region. We are also fortifying this collaboration and expanding into mobile services in order to capitalize on the growth of inbound roaming traffic.”
The Dominican Republic has experienced remarkable growth in tourism, witnessing a 14% increase in international visitors in 2023 compared to 2019, surpassing 10 million travelers for the first time.* Ensuring excellent roaming performance and experience is crucial in such an appealing destination for foreign visitors.
“With Altice Dominicana, we share the same goal of providing state-of-the-art connectivity and supporting innovations to unleash the potential of international communications,” said Edwin van Ierland, CEO of Voice & Mobile Data at iBASIS. “Thanks to our global platforms, capabilities, and highly motivated teams, iBASIS is a high-growth partner and is helping Altice Dominicana to continue to perform at the highest level.”
“The renewal with Altice Dominicana marks another significant milestone, highlighting the appeal of iBASIS's outsourcing proposition," remarked Alexandre Pébereau, Group CEO and Founder of Tofane Global. "By overseeing the entire spectrum of international voice and mobile communications for them, our customers can concentrate on their retail business, foster growth, and sustain their dominant market position.”
ABOUT iBASIS
iBASIS is the leading communications solutions provider enabling operators and digital players worldwide to perform and transform. Powered by Tofane Global, iBASIS is the first independent communications specialist and Tier One IPX vendor with 800+ LTE destinations. iBASIS today serves 1,000+ customers across 28 locations worldwide. iBASIS optimizes global connectivity, quality, and security so customers achieve high return on voice, SMS A2P messaging, mobile data, 5G roaming, and IoT. iBASIS provides the end-to-end Global Access for Things™ connectivity solution, delivering single source cellular IoT access (LTE, LTE-M and NB-IoT) worldwide provisioned through GSMA-standard eSIM/eUICC technology. For more information, please visit iBASIS.com.
ABOUT Altice Dominicana
Altice Dominicana is one of the main telecommunications companies in the Dominican Republic, with a decade-long history of offering connectivity and entertainment services.
Its robust mobile network has 98% coverage nationwide; With an extensive fiber optic network infrastructure, it provides Internet with the highest speed available on the market, up to 1,000 MB, cable television and high definition voice services to more than 4 million homes and businesses throughout the country.
Through its human team, agile, with challenging and daring thinking, it promotes innovation in everything it does and demonstrates its commitment to each of the Dominicans in providing them with access to technology to boost their growth opportunities.
*2023 Global Travel Trends Report
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514293879/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
